Gabeeva N G, Zvonkov E E, Koroleva D A, Chukavina M M, Obukhova T N, Kovrigina A M
National Research Center for Hematology, Russian Federation, Moscow, Russia.
Ter Arkh. 2018 Aug 17;90(7):96-101. doi: 10.26442/terarkh201890796-101.
Diffuse large B-cell lymphoma is categorized by gene expression profiling into germinal center (GCB) and activated B-cell (ABC) subtype, also referred to as non-germinal center B-cell (non-GCB) by immunohistochemistry. ABC DLBCL is characterized by NF-κB pathway activation and high expression of IRF4/MUM1, a key transcription factor in B cell differentiation. Patients with ABC DLBCL have a significantly worse outcome when treated with standard chemotherapy (R-CHOP). Lenalidomide have shown activity in the ABC-DLBCL in combination with R-CHOP. But about 40% of patients remain resistant. We present the experience of treatment of a patient with generalized non-GCB-DLBCL using the intensive protocol R-mNHL-BFM-90 with lenalidomide.
弥漫性大B细胞淋巴瘤通过基因表达谱分析可分为生发中心（GCB）和活化B细胞（ABC）亚型，免疫组织化学也将其称为非生发中心B细胞（非GCB）亚型。ABC弥漫性大B细胞淋巴瘤的特征是NF-κB通路激活以及IRF4/MUM1高表达，IRF4/MUM1是B细胞分化中的关键转录因子。ABC弥漫性大B细胞淋巴瘤患者接受标准化疗（R-CHOP）时预后明显较差。来那度胺与R-CHOP联合使用时已显示出对ABC弥漫性大B细胞淋巴瘤的活性。但约40%的患者仍然耐药。我们介绍了使用含来那度胺的强化方案R-mNHL-BFM-90治疗一名广泛性非GCB弥漫性大B细胞淋巴瘤患者的经验。
